Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014.
Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.
Biocorp has raised €8.9m ($9.8m) through an IPO during what it called a period of “deep macroeconomic uncertainty” and has underlined plans to grow its drug delivery tech business internationally.
Quintiles has been upgraded to stable by ratings agency Standard & Poor after a second stock offering and the consolidation of debt through a $300m securitisation facility.
The Raleigh, North Carolina-based CRO INC Research plans to raise about $150m in its initial public offering via about 8.1m shares at a price range of $17 to $20 per share.
Following pushes to go public by top peers, CRO INC Research has filed an S-1 with the SEC in preparation for an IPO (initial public offering) on the NASDAQ.
Newly public Horizon Discovery Group says it is looking for more acquisitions to become a fully integrated products, services and research provider as revenues soars 35%.
Experts have predicted more CROs will go public as Private Equity looks to get a return on its investments, but such shifts are indicative of a booming market rather than waning interest.
Recipharm AB will continue its spending spree of the past few years according to CEO Thomas Eldered, who reiterated the CMO’s plan to grow through takeovers in a results presentation earlier today.
Recipharm AB will manufacture commercial supplies of a topical formulation of the anaesthetic lidocaine called Shact that is soon to be launched by developer Pharmanest AB.
Dutch API and excipients distributor IMCD has increased the number of shares it will make available in its initial public offering (IPO), citing demand.
US CRO PRA is proposing to go public again, more than six years since it was taken private, according to a confidential draft registration statement submitted to the US SEC.
ShangPharma expects its cGMP production site, due to open in 2011, and biologics services to drive growth as it builds on a 17 per cent increase in revenues in the third quarter.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Clearstone Central Laboratories, NexMed and RRD.
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including media reports of a new CEO at Proctor & Gamble.
A planned $60-$70m (€38-€44m) initial public offering (IPO) by
US-based drug delivery specialist MonoSol Rx has fallen foul of the
credit crunch and fears about a slowing US economy.
WuXi PharmaTech, the biggest Chinese contract research organisation
(CRO), has put an end to weeks of speculation by officially
announcing it plans an initial public offering (IPO) on the New
York Stock Exchange.
Germany's Sartorius has decided to call off the initial public
offering of Vivascience, which makes products for the analysis and
purification of proteins.
The biotech industry managed to raise almost $6 billion during the
third quarter bringing the total raised this year to $20 billion
(€16.2 billion), an increase of $3.2 billion from this time last
year, reflecting the growing confidence...
Australian drug delivery company Acrux is hoping to raise A$30
million (€18m) in a float on the Australian Stock Exchange to
support the development of its novel transdermal technology that
does not require the use of adhesive patches...
Sartorius, a German manufacturer of laboratory equipment, is
considering a possible initial public offering for its
biotechnology unit Vivascience in the second half of this year,
according to local press reports.
Lanxess, the new company in which Germany's Bayer will combine
almost all areas of its chemicals business and parts of its
polymers activities, begins operating as an independent unit today.
UK encapsulation company BioProgress yesterday unveiled plans to
raise £6.6 million (€9.4m) through a placement of shares in order
to build a new pharmaceutical production plant.
Germany's Bayer has received offers to buy NewCo, the newly-created
company including parts of its chemicals and polymers divisions,
but will still go ahead with plans to float it on the stock
exchange , according to the group's...
October has seen a rush by US biotechnology companies to list on
the stock markets, bringing to an end an Initial Public Offering
(IPO) drought lasting more than 18 months. Is Europe destined to
follow?
